Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
2.380
-0.170 (-6.67%)
Nov 20, 2024, 4:00 PM EST - Market closed
Phio Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | - | - | - | - | - | 0.02 | |
| Revenue Growth (YoY) | - | - | - | - | - | -84.78% | |
| Cost of Revenue | 4.41 | 6.33 | 7.01 | 8.89 | 3.72 | 4.3 | |
| Gross Profit | -4.41 | -6.33 | -7.01 | -8.89 | -3.72 | -4.28 | |
| Selling, General & Admin | 3.74 | 4.29 | 4.45 | 4.63 | 5.08 | 4.71 | |
| Operating Expenses | 3 | 4.29 | 4.45 | 4.63 | 5.08 | 4.71 | |
| Operating Income | -7.41 | -10.62 | -11.46 | -13.51 | -8.79 | -8.99 | |
| Interest Expense | - | - | - | - | -0 | - | |
| Other Non Operating Income (Expenses) | 0.19 | -0 | -0.02 | -0.01 | - | 0.08 | |
| EBT Excluding Unusual Items | -7.22 | -10.62 | -11.48 | -13.52 | -8.79 | -8.91 | |
| Asset Writedown | -0.13 | -0.13 | - | - | - | - | |
| Other Unusual Items | -0.08 | -0.08 | - | 0.23 | - | - | |
| Pretax Income | -7.42 | -10.83 | -11.48 | -13.29 | -8.79 | -8.91 | |
| Net Income | -7.42 | -10.83 | -11.48 | -13.29 | -8.79 | -8.91 | |
| Net Income to Common | -7.42 | -10.83 | -11.48 | -13.29 | -8.79 | -8.91 | |
| Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | - | |
| Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | - | |
| Shares Change (YoY) | 227.50% | 83.32% | 6.30% | 179.70% | - | - | |
| EPS (Basic) | -12.64 | -46.76 | -90.91 | -111.84 | -207.04 | - | |
| EPS (Diluted) | -12.64 | -46.76 | -90.91 | -111.87 | -207.04 | - | |
| Free Cash Flow | -8.11 | -10.75 | -12.25 | -11.91 | -8.82 | -8.72 | |
| Free Cash Flow Per Share | -13.82 | -46.45 | -97.00 | -100.24 | -207.68 | - | |
| Operating Margin | - | - | - | - | - | -42795.24% | |
| Profit Margin | - | - | - | - | - | -42419.05% | |
| Free Cash Flow Margin | - | - | - | - | - | -41509.52% | |
| EBITDA | -7.4 | -10.56 | -11.39 | -13.44 | -8.72 | -8.92 | |
| D&A For EBITDA | 0.01 | 0.06 | 0.07 | 0.08 | 0.07 | 0.07 | |
| EBIT | -7.41 | -10.62 | -11.46 | -13.51 | -8.79 | -8.99 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.